Guizhou Bailing Group Pharmaceutical Co Ltd (002424) - Total Liabilities
Based on the latest financial reports, Guizhou Bailing Group Pharmaceutical Co Ltd (002424) has total liabilities worth CN¥2.75 Billion CNY (≈ $402.83 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002424 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Guizhou Bailing Group Pharmaceutical Co Ltd - Total Liabilities Trend (2007–2025)
This chart illustrates how Guizhou Bailing Group Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Guizhou Bailing Group Pharmaceutical Co balance sheet assets.
Guizhou Bailing Group Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guizhou Bailing Group Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥789.65 Million |
|
Cisen Pharmaceutical Co Ltd
SHG:603367
|
China | CN¥1.29 Billion |
|
Orient Semiconductor Electronics Ltd
TW:2329
|
Taiwan | NT$10.25 Billion |
|
Douglas Dynamics Inc
NYSE:PLOW
|
USA | $430.01 Million |
|
Sichuan Shudao Equipment & Technology Co Ltd
SHE:300540
|
China | CN¥966.60 Million |
|
SpyGlass Pharma, Inc.
NASDAQ:SGP
|
USA | $11.07 Million |
|
Railtel Corporation Of India Limited
NSE:RAILTEL
|
India | Rs35.68 Billion |
|
Lintes Technology Co Ltd
TW:6715
|
Taiwan | NT$888.20 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Guizhou Bailing Group Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 002424 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guizhou Bailing Group Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual total liabilities of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.02 Billion ≈ $442.32 Million |
-23.20% |
| 2024-12-31 | CN¥3.94 Billion ≈ $575.92 Million |
+2.98% |
| 2023-12-31 | CN¥3.82 Billion ≈ $559.25 Million |
+31.90% |
| 2022-12-31 | CN¥2.90 Billion ≈ $423.99 Million |
+14.56% |
| 2021-12-31 | CN¥2.53 Billion ≈ $370.09 Million |
-18.74% |
| 2020-12-31 | CN¥3.11 Billion ≈ $455.46 Million |
+6.86% |
| 2019-12-31 | CN¥2.91 Billion ≈ $426.23 Million |
+41.98% |
| 2018-12-31 | CN¥2.05 Billion ≈ $300.21 Million |
+51.35% |
| 2017-12-31 | CN¥1.36 Billion ≈ $198.35 Million |
+15.79% |
| 2016-12-31 | CN¥1.17 Billion ≈ $171.30 Million |
+0.87% |
| 2015-12-31 | CN¥1.16 Billion ≈ $169.82 Million |
-4.66% |
| 2014-12-31 | CN¥1.22 Billion ≈ $178.13 Million |
-9.95% |
| 2013-12-31 | CN¥1.35 Billion ≈ $197.81 Million |
+12.89% |
| 2012-12-31 | CN¥1.20 Billion ≈ $175.23 Million |
+11.04% |
| 2011-12-31 | CN¥1.08 Billion ≈ $157.81 Million |
+13.22% |
| 2010-12-31 | CN¥952.49 Million ≈ $139.38 Million |
+113.81% |
| 2009-12-31 | CN¥445.48 Million ≈ $65.19 Million |
+38.90% |
| 2008-12-31 | CN¥320.72 Million ≈ $46.93 Million |
+1.54% |
| 2007-12-31 | CN¥315.87 Million ≈ $46.22 Million |
-- |
About Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines … Read more